FcRn blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo) coverage for gMG and CIDP
Customize your policy alerts
Sign up for sierra health and life Policy 2026D0111N alerts
Get alerted when Policy 2026D0111N changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and prior authorization requirements for provider‑administered FcRn blocker therapies (rozanolixizumab, efgartigimod products) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) under Sierra Health and Life medical benefit.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.